{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:55:14Z","timestamp":1792130114497,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In this work, we describe a new case of association between SCA2 and MND.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>A 58-year-old man who was diagnosed with spinocerebellar ataxia type 2 presented dysphagia and a significant decline in his ability to walk, with a reduction in autonomy and the need to use a wheelchair. We performed electromyography and electroneurography of the four limbs and of the cranial district and motor-evoked potentials to study upper and lower motor neurons. Referring to the revised El Escorial criteria of 2015, ALS diagnosis was made.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Considering different cases described in literature over the years, SCA2 could represent an important risk factor for developing ALS. In particular, the presence of alleles of ATXN2 with 27 and 28 CAG repeats seems to slightly decrease the risk of developing the disease, which would instead be progressively increased by the presence of alleles with 29, 30, 31, 32, and 33 repeats. The exact physiopathological mechanism by which the mutation increases the risk of developing the disease is currently unknown. Transcriptomic studies on mouse models have demonstrated the involvement of several pathways, including the innate immunity regulation by STING and the biosynthesis of fatty acid and cholesterol by SREBP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAG repeat expansions in the ATXN2 gene have been associated with variable neurological presentations, which include SCA2, ALS, Parkinsonism, or a combination of them. Further research is needed to understand the relationship between SCA2 and ALS better and explore molecular underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-024-07521-9","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T22:37:57Z","timestamp":1713652677000},"page":"4367-4371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rare association between spinocerebellar ataxia and amyotrophic lateral sclerosis: a case series"],"prefix":"10.1007","volume":"45","author":[{"given":"Valerio","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Bovenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Cerroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Pierantozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola B.","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1806-8922","authenticated-orcid":false,"given":"Alessandro","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"key":"7521_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/acn3.437","volume":"4","author":"A Antenora","year":"2017","unstructured":"Antenora A, Rinaldi C, Roca A et al (2017) The multiple faces of spinocerebellar ataxia type 2. Ann Clin Transl Neurol 4:687\u2013695","journal-title":"Ann Clin Transl Neurol"},{"key":"7521_CR2","doi-asserted-by":"publisher","unstructured":"Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 1. https:\/\/doi.org\/10.1080\/146608200300079536","DOI":"10.1080\/146608200300079536"},{"key":"7521_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s004150050608","volume":"247","author":"S Ohara","year":"2000","unstructured":"Ohara S, Tsuyuzaki J, Hayashi R et al (2000) Motor neuron loss in a patient with spinocerebellar ataxia type 6: chance co-occurrence or causally related? J Neurol 247:386\u2013388. https:\/\/doi.org\/10.1007\/s004150050608","journal-title":"J Neurol"},{"key":"7521_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/21678421.2020.1853172","volume":"22","author":"H Ghahremani Nezhad","year":"2021","unstructured":"Ghahremani Nezhad H, Franklin JP, Alix JJP et al (2021) Simultaneous ALS and SCA2 associated with an intermediate-length ATXN2 CAG-repeat expansion. Amyotroph Lateral Scler Frontotemporal Degener 22:579\u2013582. https:\/\/doi.org\/10.1080\/21678421.2020.1853172","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"7521_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1590\/0004-282x-anp-2020-0189","volume":"79","author":"CS Jaques","year":"2021","unstructured":"Jaques CS, Pedroso JL, da Rocha AJ et al (2021) Spinocerebellar ataxia type 3 presenting simultaneously with motor neuron disease and cerebellar ataxia. Arq Neuropsiquiatr 79:851\u2013852","journal-title":"Arq Neuropsiquiatr"},{"key":"7521_CR6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/mds.20074","volume":"19","author":"S Furtado","year":"2004","unstructured":"Furtado S, Payami H, Lockhart PJ et al (2004) Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Mov Disord 19:622\u2013629","journal-title":"Mov Disord"},{"key":"7521_CR7","unstructured":"Dayes LA, Gardiner N (2005) The neurological implications of fibromuscular dysplasia.\u00a0Mt Sinai J Med\u00a072(6)"},{"key":"7521_CR8","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1007\/s00415-009-5237-9","volume":"256","author":"L Nanetti","year":"2009","unstructured":"Nanetti L, Fancellu R, Tomasello C et al (2009) Rare association of motor neuron disease and spinocerebellar ataxia type 2 (SCA2): a new case and review of the literature. J Neurol 256:1926\u20131928. https:\/\/doi.org\/10.1007\/s00415-009-5237-9","journal-title":"J Neurol"},{"key":"7521_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mds.10675","volume":"19","author":"I Sibon","year":"2004","unstructured":"Sibon I, Burbaud P (2004) Risus sardonicus after thalamic haemorrhage. Mov Disord 19:829\u2013831. https:\/\/doi.org\/10.1002\/mds.10675","journal-title":"Mov Disord"},{"issue":"5","key":"7521_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/hmg\/6.5.709","volume":"6","author":"G Cancel","year":"1997","unstructured":"Cancel G, D\u00fcrr A, Didierjean O et al (1997) Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. Hum Mol Genet 6(5):709\u2013715. https:\/\/doi.org\/10.1093\/hmg\/6.5.709","journal-title":"Hum Mol Genet"},{"issue":"1","key":"7521_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ejhg.2011.154","volume":"20","author":"JM Laffita-Mesa","year":"2012","unstructured":"Laffita-Mesa JM, Vel\u00e1zquez-P\u00e9rez LC, Santos Falc\u00f3n N et al (2012) Unexpanded and intermediate CAG polymorphisms at the SCA2 locus (ATXN2) in the Cuban population: evidence about the origin of expanded SCA2 alleles. Eur J Med Genet 20(1):41\u201349. https:\/\/doi.org\/10.1038\/ejhg.2011.154","journal-title":"Eur J Med Genet"},{"key":"7521_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature09320","volume":"466","author":"AC Elden","year":"2010","unstructured":"Elden AC, Kim HJ, Hart MP et al (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466:1069\u20131075. https:\/\/doi.org\/10.1038\/nature09320","journal-title":"Nature"},{"key":"7521_CR13","doi-asserted-by":"publisher","unstructured":"Sproviero W, Shatunov A, Stahl D et al (2017) ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol Aging 51:178\u2013e1. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.11.010","DOI":"10.1016\/j.neurobiolaging.2016.11.010"},{"key":"7521_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaneurol.2014.2082","volume":"71","author":"AG Neuenschwander","year":"2014","unstructured":"Neuenschwander AG, Thai KK, Figueroa KP, Pulst SM (2014) Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis. JAMA Neurol 71:1529\u20131534. https:\/\/doi.org\/10.1001\/jamaneurol.2014.2082","journal-title":"JAMA Neurol"},{"key":"7521_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00439-011-1000-2","volume":"130","author":"L Corrado","year":"2011","unstructured":"Corrado L, Mazzini L, Oggioni GD et al (2011) ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum Genet 130:575\u2013580. https:\/\/doi.org\/10.1007\/s00439-011-1000-2","journal-title":"Hum Genet"},{"key":"7521_CR16","doi-asserted-by":"publisher","unstructured":"Kim J-M, Hong S, Gyoung et al (2007) Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism.\u00a0Arch Neurol\u00a064(10):1510\u20131518. https:\/\/doi.org\/10.1001\/archneur.64.10.1510","DOI":"10.1001\/archneur.64.10.1510"},{"issue":"3","key":"7521_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1212\/WNL.0000000000001159","volume":"84","author":"A Chi\u00f2","year":"2015","unstructured":"Chi\u00f2 A, Calvo A, Moglia C et al (2015) ATXN2 polyQ intermediate repeats are a modifier of ALS survival. Neurology 84(3):251\u2013258. https:\/\/doi.org\/10.1212\/WNL.0000000000001159","journal-title":"Neurology"},{"issue":"11","key":"7521_CR18","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1136\/jnnp-2022-329376","volume":"93","author":"A Chio","year":"2022","unstructured":"Chio A, Moglia C, Canosa A et al (2022) Exploring the phenotype of Italian patients with ALS with intermediate ATXN2 polyQ repeats. J Neurol Neurosurg Psychiatry 93(11):1216\u20131220. https:\/\/doi.org\/10.1136\/jnnp-2022-329376","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7521_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nature22038","volume":"544","author":"LA Becker","year":"2017","unstructured":"Becker LA, Huang B, Bieri G et al (2017) Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544:367\u2013371. https:\/\/doi.org\/10.1038\/nature22038","journal-title":"Nature"},{"key":"7521_CR20","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/hmg\/ddaa072","volume":"29","author":"DR Scoles","year":"2020","unstructured":"Scoles DR, Dansithong W, Pflieger LT et al (2020) ALS-associated genes in SCA2 mouse spinal cord transcriptomes. Hum Mol Genet 29:1658\u20131672. https:\/\/doi.org\/10.1093\/hmg\/ddaa072","journal-title":"Hum Mol Genet"},{"key":"7521_CR21","doi-asserted-by":"publisher","unstructured":"Kim G, Nakayama L, Blum JA et al (2022) Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. Cell Reports 41(4). https:\/\/doi.org\/10.1016\/j.celrep.2022.111508","DOI":"10.1016\/j.celrep.2022.111508"},{"key":"7521_CR22","doi-asserted-by":"publisher","unstructured":"McLoughlin HS, Moore LR, Paulson HL (2020) Pathogenesis of SCA3 and implications for other polyglutamine diseases. Neurobiol Dis 134:104635.\u00a0https:\/\/doi.org\/10.1016\/j.nbd.2019.104635","DOI":"10.1016\/j.nbd.2019.104635"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07521-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07521-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07521-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T06:35:48Z","timestamp":1723012548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07521-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["7521"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07521-9","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in agreement with the principles of the Helsinki declarations. The ethical committee of \u201cPoliclinico Tor Vergata\u201d approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the subject involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}